| Name | Title | Contact Details |
|---|
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Syncom is the first pharmaceutical contract sales force company to offer electronic state-of-the-art Call Planning, Call Reporting, Sample Accountability, and Data Management. Syncom Pharmaceutical Sales Representatives armed with the SESMS afford you
WellCentive is a pioneer in business and clinical intelligence registry EHR healthcare information technology.
SkinCareRx is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eden Organix is a Highland Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.